c19early.org COVID-19 treatment researchCOVID-19 treatments

Supplementary Data — Ibuzatrelvir for COVID-19: real-time meta-analysis of 1 study

@CovidAnalysis, November 2026, Version 1V1

Ibuzatrelvir COVID-19 outcomes

c19early.org
November 2026
StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Mortezavi (DB RCT)27%0.73 · 0.62–0.85viral load66 (n)60 (n) Mortezavi (DB RCT)20%0.80 · 0.67–0.95viral load24 (n)60 (n) Mortezavi (DB RCT)18%0.82 · 0.70–0.97viral load34 (n)60 (n) Mortezavi (DB RCT)48%0.52 · 0.38–0.72viral load70 (n)63 (n) Mortezavi (DB RCT)48%0.52 · 0.37–0.74viral load27 (n)63 (n) Mortezavi (DB RCT)35%0.65 · 0.46–0.92viral load35 (n)63 (n)
00.511.52+
Rotate screen for more detailsIncrease width for more details
← Ibuzatrelvir
reduces riskIbuzatrelvir
increases risk →
Fig. S1. All outcomes.
Loading..
Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.